BioNTech Continues AHEAD-MERIT Trial Despite BNT113's PFS Endpoint Miss

BioNTech's (BNTX) BNT113 vaccine failed to meet a key endpoint in a clinical trial, causing shares to slide. The company's P/S ratio is 7.09, above its historical median, but it remains unprofitable. Insiders have sold $89.8M in shares over the past year, and analysts are cautious about its oncology pipeline.

BioNTech's BNT113 failed to meet a primary endpoint in a phase 2/3 trial for head and neck cancer, causing its stock to drop ~6% in Tuesday trading. The AHEAD-MERIT study is ongoing. According to the company, the therapy did not achieve the required progression-free survival rate. Investors reacted negatively to the news, impacting the company's stock price.

BioNTech's mRNA cancer therapy BNT113 failed to improve progression-free survival in a Phase 3 trial for head and neck cancer. The trial will continue to assess overall survival. Shares fell 5% to $90.88. BMO Capital Markets expressed reduced confidence in the therapy's success.

BioNTech's experimental mRNA cancer treatment, BNT113, combined with Merck's Keytruda, failed to meet the primary endpoint in a clinical trial for head and neck cancer. The drug did not show a statistically significant improvement in progression-free survival compared to Keytruda alone. BioNTech's U.S.-listed shares fell nearly 6% in premarket trading. The trial will continue to assess overall survival.

BioNTech's (BNTX) shares dropped 5% after its cancer therapy BNT113 failed to meet the primary endpoint of improving progression-free survival in a clinical trial for HPV-associated head and neck cancer. The trial will continue to assess overall survival, a key objective. BioNTech remains blinded to ongoing data, and no timeline for final results was provided.

BioNTech's experimental mRNA cancer immunotherapy, BNT113, combined with Merck's Keytruda, failed to meet the primary goal of improving progression-free survival in a mid-to-late-stage trial for head and neck cancer. Shares fell nearly 6% in premarket trading. The trial will continue to assess overall survival. According to Citi analyst Geoffrey Meacham, the results were disappointing but not unexpected due to the disease's complexity.